scholarly journals Crosstalk of Magnesium and Serum Lipids in Dyslipidemia and Associated Disorders: A Systematic Review

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1411
Author(s):  
Mihnea-Alexandru Găman ◽  
Elena-Codruța Dobrică ◽  
Matei-Alexandru Cozma ◽  
Ninel-Iacobus Antonie ◽  
Ana Maria Alexandra Stănescu ◽  
...  
Keyword(s):  
Lipid Profile ◽  
Serum Lipids ◽  
The Body ◽  
Lipid Lowering ◽  
Cochrane Library ◽  
The Metabolic Syndrome ◽  
The Cochrane Library ◽  
Lipid Lowering Agents ◽  
Lipid Abnormalities ◽  
The Impact

Dyslipidemia is a significant threat to public health worldwide and the identification of its pathogenic mechanisms, as well as novel lipid-lowering agents, are warranted. Magnesium (Mg) is a key element to human health and its deficiency has been linked to the development of lipid abnormalities and related disorders, such as the metabolic syndrome, type 2 diabetes mellitus, or cardiovascular disease. In this review, we explored the associations of Mg (dietary intake, Mg concentrations in the body) and the lipid profile, as well as the impact of Mg supplementation on serum lipids. A systematic search was computed in PubMed/MEDLINE and the Cochrane Library and 3649 potentially relevant papers were detected and screened (n = 3364 following the removal of duplicates). After the removal of irrelevant manuscripts based on the screening of their titles and abstracts (n = 3037), we examined the full-texts of 327 original papers. Finally, after we applied the exclusion and inclusion criteria, a number of 124 original articles were included in this review. Overall, the data analyzed in this review point out an association of Mg concentrations in the body with serum lipids in dyslipidemia and related disorders. However, further research is warranted to clarify whether a higher intake of Mg from the diet or via supplements can influence the lipid profile and exert lipid-lowering actions.

scholarly journals Zinc and the Innovative Zinc-α2-Glycoprotein Adipokine Play an Important Role in Lipid Metabolism: A Critical Review

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2023
Author(s):  
Michalina Banaszak ◽  
Ilona Górna ◽  
Juliusz Przysławski
Keyword(s):  
Lipid Metabolism ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
The Body ◽  
Zinc Homeostasis ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Blood Concentrations ◽  
The Metabolic Syndrome ◽  
Cardiovascular Morbidity And Mortality

Numerous studies indicate that zinc and the new zinc-related adipokine, zinc-α2-glycoprotein (ZAG), are involved in lipid metabolism. Excess body fat lowers blood concentrations of Zn and ZAG, leading not only to the development of obesity but also to other components of the metabolic syndrome. Zinc homeostasis disorders in the body negatively affect the lipid profile and cytokine secretion. Zinc appears to be a very important ZAG homeostasis regulator. The physiological effects of ZAG are related to lipid metabolism, but studies show that ZAG also affects glucose metabolism and is linked to insulin resistance. ZAG has a zinc binding site in its structure, which may indicate that ZAG mediates the effect of zinc on lipid metabolism. The review aimed to verify the available studies on the effects of zinc and ZAG on lipid metabolism. A literature review within the scope of this research area was conducted using articles available in PubMed (including MEDLINE), Web of Science and Cochrane Library databases. An analysis of available studies has shown that zinc improves hepatic lipid metabolism and has an impact on the lipid profile. Numerous studies have found that zinc supplementation in overweight individuals significantly reduced blood levels of total cholesterol, LDL (Low-density lipoprotein)cholesterol and triglycerides, potentially reducing cardiovascular morbidity and mortality. Some results also indicate that it increases HDL-C (High-density lipoprotein) cholesterol levels. ZAG has been shown to play a significant role in reducing obesity and improving insulin sensitivity, both in experimental animal model studies and in human studies. Furthermore, ZAG at physiologically relevant concentrations increases the release of adiponectin from human adipocytes. In addition, ZAG has been shown to inhibit in vitro leptin production. Further studies are needed to provide more data on the role of zinc and zinc-α2-glycoprotein.

scholarly journals Ezetimibe in the Treatment of Patients with Metabolic Diseases

2013 ◽  
Vol 09 (01) ◽  
pp. 55
Author(s):  
Mayssam A Nehme ◽  
Ashish Upadhyay ◽  
◽  
Keyword(s):  
Lipid Profile ◽  
Metabolic Diseases ◽  
Cardiovascular Outcomes ◽  
Lipid Lowering ◽  
Favorable Effect ◽  
Special Focus ◽  
Established Risk Factor ◽  
The Metabolic Syndrome ◽  
The Impact

Dyslipidemia is an established risk factor for cardiovascular disease. While statin therapy remains the most important component of dyslipidemia management, a substantial proportion of patients on statin monotherapy fails to achieve guideline-recommended lipid levels. Ezetimibe is a secondline lipid-lowering agent that reduces sterol absorption, and has a favorable effect on lipid profile. This article reviews studies examining the role of ezetimibe on lipid profile, metabolic biomarkers, and cardiovascular outcomes in individuals with metabolic diseases. Special focus is given to studies in patients with dyslipidemia, Type 2 diabetes, and the metabolic syndrome. The controversy surrounding the role of ezetimibe in mitigating atherosclerosis is also highlighted. The article concludes that the ezetimibe–statin combination improves lipid parameters and helps attain guidelinerecommended lipid goals in patients with metabolic diseases. However, further research is needed to better understand the role of ezetimibe monotherapy, and the impact of ezetimibe on clinical cardiovascular outcomes.

scholarly journals Ezetimibe in the Treatment of Patients with Metabolic Diseases

2010 ◽  
Vol 9 (1) ◽  
pp. 55
Author(s):  
Mayssam A Nehme MD ◽  
Ashish Upadhyay MD ◽  
◽  
Keyword(s):  
Lipid Profile ◽  
Metabolic Diseases ◽  
Cardiovascular Outcomes ◽  
Lipid Lowering ◽  
Favorable Effect ◽  
Special Focus ◽  
Established Risk Factor ◽  
The Metabolic Syndrome ◽  
The Impact

Dyslipidemia is an established risk factor for cardiovascular disease. While statin therapy remains the most important component of dyslipidemia management, a substantial proportion of patients on statin monotherapy fails to achieve guideline-recommended lipid levels. Ezetimibe is a secondline lipid-lowering agent that reduces sterol absorption, and has a favorable effect on lipid profile. This article reviews studies examining the role of ezetimibe on lipid profile, metabolic biomarkers, and cardiovascular outcomes in individuals with metabolic diseases. Special focus is given to studies in patients with dyslipidemia, Type 2 diabetes, and the metabolic syndrome. The controversy surrounding the role of ezetimibe in mitigating atherosclerosis is also highlighted. The article concludes that the ezetimibe–statin combination improves lipid parameters and helps attain guidelinerecommended lipid goals in patients with metabolic diseases. However, further research is needed to better understand the role of ezetimibe monotherapy, and the impact of ezetimibe on clinical cardiovascular outcomes.

Appendectomy Does Not Increase the Risk of Future Emergence of Parkinson’s Disease: A Meta-analysis

2021 ◽  
pp. 000313482198903
Author(s):  
Mitsuru Ishizuka ◽  
Norisuke Shibuya ◽  
Kazutoshi Takagi ◽  
Hiroyuki Hachiya ◽  
Kazuma Tago ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Random Effects Models ◽  
Significant Difference ◽  
The Cochrane Library ◽  
The Impact ◽  
The Relationship ◽  
Observation Period

Objective To explore the impact of appendectomy history on emergence of Parkinson’s disease (PD). Background Although there are several studies to investigate the relationship between appendectomy history and emergence of PD, the results are still controversial. Methods We performed a comprehensive electronic search of the literature (the Cochrane Library, PubMed, and the Web of Science) up to April 2020 to identify studies that had employed databases allowing comparison of emergence of PD between patients with and those without appendectomy history. To integrate the impact of appendectomy history on emergence of PD, a meta-analysis was performed using random-effects models to calculate the risk ratio (RR) and 95% confidence interval (CI) for the selected studies, and heterogeneity was analyzed using I2 statistics. Results Four studies involving a total of 6 080 710 patients were included in this meta-analysis. Among 1 470 613 patients with appendectomy history, 1845 (.13%) had emergences of PD during the observation period, whereas among 4 610 097 patients without appendectomy history, 6743 (.15%) had emergences of PD during the observation period. These results revealed that patients with appendectomy history and without appendectomy had almost the same emergence of PD (RR, 1.02; 95% CI, .87-1.20; P = .83; I2 = 87%). Conclusion This meta-analysis has demonstrated that there was no significant difference in emergence of PD between patients with and those without appendectomy history.

scholarly journals Excess weight and dyslipidemia and their complications during pregnancy: a systematic review

2016 ◽  
Vol 16 (2) ◽  
pp. 93-101 ◽  
Author(s):  
Iramar Baptistella do Nascimento ◽  
Willian Barbosa Sales ◽  
Raquel Fleig ◽  
Grazielle Dutra da Silva ◽  
Jean Carl Silva
Keyword(s):  
Systematic Review ◽  
Key Words ◽  
Excess Weight ◽  
Cochrane Library ◽  
Obstetric Outcomes ◽  
Lipid Disorders ◽  
Key Words Lipids ◽  
The Cochrane Library ◽  
The Impact ◽  
In Pregnancy

Abstract Objectives: to identify bibliographically disorders related to excess weight, dyslipidemia and their complication during pregnancy and in the fetus and newborn. Methods: a systematic review including observational and interventional studies and reviews, based on MEDLINE, LILACS, Embase and the Cochrane Library between 2000 and 2015. The key-words "lipids, pregnancy, obesity and newborn" were used to establish a selective stage for inclusion/exclusion of titles, repeated studies, key-words, abstracts, methodological incompatibility and correlation with objectives. Results: 58 studies were selected, of which 36 (62%) addressed prevention and the risk in pregnancy of excess weight and lipid disorders and 19 (32.7%) suggestions and/or consequences for the fetus and newborn. Conclusions: excess weight and lipidemic disorders in pregnancy are causes for concern in scientific studies, posing risks both for the mother and the newborn. Higher prevalence of caesarian and pre-eclampsia were the two most noteworthy complications for gestational outcomes. In short, the impact on care of maternal habits and excess weight during pregnancy is highly significant, owing to the different degrees of complication in obstetric outcomes and their influence on the clinical characteristics of the newborn.

scholarly journals Hygienic assessment of the impact of 5G/IMT-2020 communication networks on public health (literature review)

2021 ◽  
Vol 100 (9) ◽  
pp. 929-932
Author(s):  
Anna M. Egorova ◽  
Lydiya A. Lutsenko ◽  
Anna V. Sukhova ◽  
Vyacheslav V. Kolyuka ◽  
Rustam V. Turdyev
Keyword(s):  
Public Health ◽  
Radio Frequency ◽  
Electromagnetic Radiation ◽  
Communication Networks ◽  
Biological Effects ◽  
Three Dimensional ◽  
Cochrane Library ◽  
Pubmed Search ◽  
The Cochrane Library ◽  
The Impact

The program “Digital Economy of the Russian Federation” approved the Concept for the creation and development of 5G / IMT-2020 networks. The development of 5G communications will significantly impact the implementation of many innovative projects and initiatives: the Smart City project, Unmanned Transport, etc. Along with significant technical advantages compared to previous generations of communication (2G, 3G, 4G), 5G technology has completely different emitting characteristics: more emitting elements, signal modulation, three-dimensional beam, the ability to control the beam, SHF (ultra-high) and EHF (extremely high) radio frequency ranges and centimetre and millimetre wavelengths of electromagnetic radiation. Therefore, it is becoming an especially urgent problem to ensure exposure to the human body of non-ionizing electromagnetic fields of the radio frequency range (30 kHz-300 GHz). The authors searched the literature on the biological effects of 5G cellular communications and electromagnetic radiation in the centimetre and millimetre ranges using the appropriate keywords in PubMed search engines, Scopus, Web of Science, Medline, The Cochrane Library, EMBASE, Global Health, CyberLeninka, RSCI and others. There is currently tentative and conflicting evidence on the impact of 5G. The rapidly growing density of wireless devices and antennas (considering future 5G networks) increases the public health risk from exposure to RF EMFs as the penetration depth for 5G EHF radiation is only a few millimetres. At these wavelengths, resonance phenomena are possible at the cellular and molecular levels, particularly concerning stimulating SHF and EHF oxidative processes and damaging DNA. The influence of the millimetre range of RF-EMF is poorly understood; oncological and non-oncological (impact on the reproductive, immune systems, etc.) effects are possible. Using numerical simulation methods of EMF radiation resonances on insects, Thielens A et al., 2018, found a significant overall increase in the absorbed RF power at a frequency of 6 GHz and higher than a frequency below 6 GHz.

Outcomes of digital biomarker-based interventions: protocol for a systematic review of systematic reviews (Preprint)

2021 ◽  
Author(s):  
Hossein Motahari-Nezhad ◽  
Márta Péntek ◽  
László Gulácsi ◽  
Zsombor Zrubka
Keyword(s):  
Clinical Outcomes ◽  
Systematic Reviews ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Level Of Evidence ◽  
Clinical Benefits ◽  
The Cochrane Library ◽  
The Impact ◽  
Digital Biomarkers

BACKGROUND Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. For their widespread adoption in publicly financed healthcare systems, it is important to understand how their benefits translate into improved patient outcomes, which is essential for demonstrating their value. OBJECTIVE To assess the quality and strength of evidence of the impact of digital biomarkers on clinical outcomes compared to interventions without digital biomarkers, reported in systematic reviews. METHODS A comprehensive search for 2019-2020 will be conducted in the PubMed and the Cochrane Library using keywords related to digital biomarkers and a filter for systematic reviews. Original full-text English publications of systematic reviews comparing clinical outcomes of interventions with and without digital biomarkers via meta-analysis will be included. The AMSTAR-2 tool will be used to assess the methodological quality of reviews. To assess the quality of evidence, we will evaluate systematic reviews using the GRADE tool. To detect the possible presence of reporting bias, we will record whether the protocol of the systematic reviews was published before the start of the study. A qualitative summary of results by digital biomarker technology and outcome will be provided. RESULTS This protocol was submitted before data collection. The next steps in this review will be initiated after the protocol is accepted for publication. CONCLUSIONS Our study will provide a comprehensive summary of the highest level of evidence available on digital biomarker interventions. Our results will help identify clinical areas where the use of digital biomarkers leads to favorable clinical outcomes. In addition, our findings will highlight areas of evidence gaps where the clinical benefits of digital biomarkers have not yet been demonstrated.

Association between Atopic Dermatitis and the Metabolic Syndrome: A Systematic Review

Dermatology ◽  
2018 ◽  
Vol 234 (3-4) ◽  
pp. 79-85 ◽  
Author(s):  
Zarqa Ali ◽  
Charlotte Suppli Ulrik ◽  
Tove Agner ◽  
Simon Francis Thomsen
Keyword(s):  
Metabolic Syndrome ◽  
Atopic Dermatitis ◽  
Central Obesity ◽  
Current Knowledge ◽  
Positive Association ◽  
Cochrane Library ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Meta Analyses ◽  
The Cochrane Library

Atopic dermatitis (AD) may be associated with the metabolic syndrome and by that carry an increased risk of cardio­vascular disease. Our objective was to provide an update on current knowledge of the association between AD and metabolic syndrome, including each component of the metabolic syndrome. A systematic literature review was performed to identify studies investigating the association between metabolic syndrome and AD from PubMed, Embase, and the Cochrane Library in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. A total of 14 studies, investigating the association between AD and the metabolic syndrome or AD and components of metabolic syndrome fulfilled the inclusion criteria and were included. It seems unlikely that the association between AD and metabolic syndrome is causal. However, women with AD tended to have components of metabolic syndrome more often than women without AD. There was a positive association between AD and central obesity measured as waist circumference, and this association was stronger for women than men. Despite conflicting results regarding hypertension, the association between hypertension and AD also appeared stronger for women. On the other hand, the association between AD and hyperglycemia appears unlikely, and the association between AD and cholesterol levels was inconsistent. In conclusion, it remains unclear whether AD is a risk factor for metabolic syndrome and its components. However, data indicate that central obesity is associated with AD and that the association is stronger for women than men.

scholarly journals Itch in Chronic Wounds: Pathophysiology, Impact, and Management

Medicines ◽  
2019 ◽  
Vol 6 (4) ◽  
pp. 112 ◽  
Author(s):  
Michela Iannone ◽  
Agata Janowska ◽  
Valentina Dini ◽  
Giulia Tonini ◽  
Teresa Oranges ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Wounds ◽  
Management Strategies ◽  
Relevant Information ◽  
Cochrane Library ◽  
Tissue Edema ◽  
Practical Guidelines ◽  
The Cochrane Library ◽  
The Impact

Background: The aims of this review are to analyze the current literature regarding the characteristics and pathophysiological mechanisms of itch in chronic wounds, to assess the impact on quality of life and delayed-healing, to focus on the best strategies of prevention and treatment, to highlight the importance of on-going research in order to fully understand the pathophysiology, and to improve the management of target therapies. Methods: A systematic literature review was performed using MEDLINE, PubMed, Embase, Scopus, ScienceDirect, and the Cochrane Library. We included a total of 11 articles written in English with relevant information on the pathophysiology of itch in chronic wounds and on management strategies. Results: Itch in chronic wounds was found to be correlated with xerosis, larger wound areas, necrotic tissue and amount of exudate, peripheral tissue edema, sclerosis, granulation tissue, contact dermatitis, and bacterial burden, as well as with lower quality of life. Conclusions: Although there are several aspecific pharmacological and non-pharmacological approaches, there appears to be no validated prevention or management strategy for itch in chronic wounds. Further studies are needed to clarify the association and pathophysiology of itch in chronic wounds, to evaluate the safety and efficacy of topical treatments on perilesional skin to reduce itch, to characterize multidimensional sensations of itch in chronic wounds, to identify specific cytokine and chemokine expressions that are correlated to a tailored-based approach, and to develop practical guidelines.

scholarly journals Metabolic Syndrome Increases the Risk for Knee Osteoarthritis: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Huajun Wang ◽  
Yanmei Cheng ◽  
Decheng Shao ◽  
Junyuan Chen ◽  
Yuan Sang ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Knee Osteoarthritis ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Significant Heterogeneity ◽  
Metabolic Factors ◽  
Knee Oa ◽  
The Metabolic Syndrome ◽  
The Cochrane Library ◽  
The Relationship

Background. Studies revealed that metabolic factors might contribute substantially to osteoarthritis (OA) pathogenesis. There has been an increasing interest to understand the relationship between knee OA and the metabolic syndrome (MetS). The purpose of this study was to explore the association between metabolic syndrome and knee osteoarthritis using meta-analysis.Methods. Databases, including PUBMED, EMBASE, and the Cochrane Library, were searched to get relevant studies. Data were extracted separately by two authors and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated.Results. The meta-analysis was finished with 8 studies with a total of 3202 cases and 20968 controls finally retrieved from the database search. The crude pooled OR is 2.24 (95% CI = 1.38–3.64). Although there was significant heterogeneity among these studies, which was largely accounted for by a single study, the increase in risk was still significant after exclusion of that study. The pooled adjusted OR remained significant with pooled adjusted OR 1.05 (95% CI = 1.03–1.07,p<0.00001). No publication bias was found in the present meta-analysis.Conclusions. The synthesis of available evidence supports that metabolic syndrome increases the risk for knee osteoarthritis, even after adjustment for many risk factors.

Sign in / Sign up

Export Citation Format

Share Document